Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors.

Tang WZ., Liao CY., Xu HY., Huang WT., Wu ZX., Chen TY.

Narrative Review on Chronic Inflammation, Immune Modulation, published in Front Immunol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Immunol (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
42266690
DOI
10.3389/fimmu.2026.1846799

Abstract (original English)

Atopic dermatitis (AD) is a complex chronic inflammatory skin disease whose pathogenesis involves a vicious cycle of epidermal barrier defects, immune dysregulation, and microbial imbalance. Despite advances in targeted biologics and small-molecule drugs, there remains an unmet clinical need for safe, effective treatments that can simultaneously intervene in multiple pathological processes. Extracellular vesicles (EVs), as key mediators of intercellular communication, play an increasingly prominent dual role in the pathophysiology and treatment of AD. This review systematically elaborates on this dialectical unity of EVs in AD. In terms of pathological mechanisms, EVs derived from pathogens such as Staphylococcus aureus and Malassezia spp., as well as from host mast cells, act as active "nanoscale pathological messengers" that deeply participate in disease initiation and progression by delivering virulence factors, disrupting the skin barrier, driving Th2/Th17 immune polarization, and sustaining chronic inflammation. Regarding therapeutic applications, therapeutic EVs derived from mesenchymal stem cells (e.g., adipose-, umbilical cord-derived), plants, probiotics, and marine organisms serve as efficient "cell-free therapeutic platforms, " demonstrating great potential for intervening in AD through multipathway immunomodulation, active restoration of barrier function, and system

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansExtracellular VesiclesDermatitis, AtopicAnimalsMast CellsStaphylococcus aureusMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research